Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00642694 · ClinicalTrials.gov registry record · Phase 3
Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon
A Phase 3 study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- Phase 3
- Development phase
- 29
- Enrollment target
NCT00642694 is a Phase 3 study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 29 participants.
The verdict
NCT00642694, a Phase 3 study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 29 participants
- Enrollment target
Study Summary
Hypothesis I: Patients in the SSRI + ramelteon treatment group will achieve remission (defined as an IDS-C30 score of 11 or less) more quickly than those in the SSRI + placebo group.
Interventions
- OTHER Placebo
- DRUG Escitalopram
- DRUG Ramelteon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00642694
The ClinicalTrials.gov registry entry for NCT00642694 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00642694 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00642694 about?
NCT00642694 is a clinical study titled "Time to Remission of Depressive Symptoms With Combined SSRI and Ramelteon". Hypothesis I: Patients in the SSRI + ramelteon treatment group will achieve remission (defined as an IDS-C30 score of 11 or less) more quickly than those in the SSRI + placebo group.
What is the current status of trial NCT00642694?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 29 participants. The study started on 2007-05. Estimated completion is 2010-05.
What interventions are being tested in trial NCT00642694?
The interventions under investigation include: Placebo (OTHER), Escitalopram (DRUG), Ramelteon (DRUG).
Who is sponsoring clinical trial NCT00642694?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.